Evangelisches Krankenhaus Duesseldorf
- Address
- lock Available on a paid plan
Respiratory Medicine and Paediatric Allergy and Asthma
At Evangelisches Krankenhaus Duesseldorf, clinical research in this area focuses on respiratory tract diseases in young children, especially recurrent infections with wheezing and preschool asthma. The trials are designed to explore better ways to reduce symptoms, prevent flare-ups, and improve day-to-day breathing health in children.
- Reducing respiratory tract infections linked to wheezing in infants and toddlers
- Preventing severe asthma exacerbations in children with partial or uncontrolled asthma
- Evaluating treatments aimed at improving paediatric respiratory health
These studies reflect a strong interest in finding more effective, child-friendly approaches to managing common and burdensome breathing problems.
Dermatology and Skin Disease Prevention
This site is also involved in research on skin and connective tissue diseases, with a particular focus on preventing atopic dermatitis in infants at high risk. The work examines whether early skin care strategies can lower the chance of developing eczema and support healthier skin in early childhood.
- Preventing atopic dermatitis in children with a strong family risk
- Testing whether regular skin care can reduce early eczema development
- Supporting better prevention strategies for paediatric skin disease
The research reflects an emphasis on early intervention and disease prevention rather than treatment after symptoms are fully established.
Infectious Disease Prevention and Immunization Research
Clinical trials at this hospital include work in bacterial infections and mycoses, especially studies of pneumococcal immunization in healthy infants. These projects are aimed at strengthening protection against serious bacterial disease through improved vaccination strategies.
- Assessing immune responses to pneumococcal vaccines in infants
- Comparing vaccine performance to improve infection prevention
- Supporting broader efforts in paediatric immunology and public health
The research contributes to understanding how best to protect young children from common and potentially dangerous bacterial infections.
Gastroenterology and Digestive System Disease Research
In the area of digestive system diseases, the site is involved in studies for adults after endoscopic treatment of oesophageal cancer-related lesions. The main goal is to improve recovery after surgery by preventing oesophageal strictures, which can make swallowing difficult and affect quality of life.
- Preventing oesophageal strictures after endoscopic treatment
- Testing new supportive approaches for recovery in digestive tract disease
- Improving outcomes after treatment for oesophageal conditions
These trials focus on making post-procedure care safer and more effective for patients undergoing advanced gastrointestinal treatment.
Oncology and Cancer Therapy Research
The research portfolio also includes neoplasms, particularly extrahepatic cholangiocarcinoma, a rare bile duct cancer. Studies in this field are exploring whether combining different treatment approaches can improve control of the disease and offer better options for patients with limited alternatives.
- Evaluating new treatment combinations for extrahepatic cholangiocarcinoma
- Studying ways to improve cancer treatment effectiveness
- Exploring innovative approaches for difficult-to-treat bile duct cancer
At Klinik für Kinder und Jugendliche, this adds a broader clinical research dimension beyond paediatric care, linking the site to targeted cancer treatment development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Evangelisches Krankenhaus Duesseldorf
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy (VITESSE) | Dbv Technologies | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Budesonide | 2 | Unknown | 2020-05-12 | 2024-08-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
